Connor Clark & Lunn Investment Management Ltd. Has $2.69 Million Stock Position in ChromaDex Co. (NASDAQ:CDXC)

Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of ChromaDex Co. (NASDAQ:CDXCFree Report) by 189.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 506,186 shares of the company’s stock after acquiring an additional 331,014 shares during the period. Connor Clark & Lunn Investment Management Ltd.’s holdings in ChromaDex were worth $2,685,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. Los Angeles Capital Management LLC acquired a new stake in ChromaDex during the 4th quarter worth approximately $1,159,000. Raymond James Financial Inc. acquired a new stake in shares of ChromaDex during the fourth quarter worth $818,000. BNP Paribas Financial Markets boosted its position in shares of ChromaDex by 1,885.7% in the third quarter. BNP Paribas Financial Markets now owns 73,272 shares of the company’s stock valued at $267,000 after acquiring an additional 69,582 shares during the period. State Street Corp grew its stake in shares of ChromaDex by 11.3% in the third quarter. State Street Corp now owns 618,028 shares of the company’s stock valued at $2,256,000 after acquiring an additional 62,692 shares in the last quarter. Finally, Barclays PLC increased its position in ChromaDex by 322.1% during the third quarter. Barclays PLC now owns 70,072 shares of the company’s stock worth $256,000 after acquiring an additional 53,472 shares during the period. Institutional investors own 15.41% of the company’s stock.

ChromaDex Stock Up 1.3 %

Shares of ChromaDex stock opened at $7.94 on Tuesday. ChromaDex Co. has a 12-month low of $2.31 and a 12-month high of $9.18. The company has a market capitalization of $617.34 million, a price-to-earnings ratio of 794.79 and a beta of 2.21. The firm’s 50-day moving average price is $6.06 and its two-hundred day moving average price is $5.39.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on CDXC shares. StockNews.com lowered shares of ChromaDex from a “strong-buy” rating to a “buy” rating in a research report on Thursday, March 6th. HC Wainwright reiterated a “buy” rating and issued a $11.00 price target on shares of ChromaDex in a research note on Monday. Finally, LADENBURG THALM/SH SH raised their price objective on ChromaDex from $6.80 to $8.10 and gave the stock a “buy” rating in a research note on Wednesday, March 5th.

View Our Latest Analysis on ChromaDex

ChromaDex Profile

(Free Report)

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.

Featured Stories

Want to see what other hedge funds are holding CDXC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ChromaDex Co. (NASDAQ:CDXCFree Report).

Institutional Ownership by Quarter for ChromaDex (NASDAQ:CDXC)

Receive News & Ratings for ChromaDex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChromaDex and related companies with MarketBeat.com's FREE daily email newsletter.